Peter Sandercock
0000-0001-8484-0135
Publication & Citation Trends
Publications
0 total
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Cited by 4
Semantic Scholar
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Cited by 14
Semantic Scholar
Accuracy of healthcare systems data for identifying cardiovascular outcomes after stroke due to intracerebral haemorrhage in the United Kingdom OA
Cited by 2
Semantic Scholar
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial OA
Cited by 64
Semantic Scholar
Exploring the role and function of trial steering committees: results of an expert panel meeting OA
Cited by 25
Semantic Scholar
Blood markers for the prognosis of ischemic stroke: a systematic review. OA
Cited by 102
Semantic Scholar
Investigation of acute stroke: what is the most effective strategy? OA
Cited by 9
Semantic Scholar
Preventing Stroke by the Modification of Risk Factors
Cited by 74
Semantic Scholar
Research Topics
Acute Ischemic Stroke Management
(367)
Cerebrovascular and Carotid Artery Diseases
(180)
Venous Thromboembolism Diagnosis and Management
(92)
Stroke Rehabilitation and Recovery
(92)
Intracerebral and Subarachnoid Hemorrhage Research
(41)
Affiliations
University of London
Oslo University Hospital
University of Sydney
University Hospitals Birmingham NHS Foundation Trust
Royal Society of Edinburgh